The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2

Cancer Letters

Volumn 337, Issue 2, 2013, Pages 237-247

  Li, Juan ^a   Cheng, Yanna ^a   Zhang, Xinke ^a   Zheng, Lei ^b   Han, Zhen ^a   Li, Pingli ^a   Xiao, Yuliang ^a   Zhang, Qian ^a   Wang, Fengshan ^a  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Traffic Hospital   (China)

Author keywords

Immunoregulatory activity; Surface plasmon resonance; Synergistic anti tumor activity; Thymosin 1 thymopentin; Toll like receptor 2

Indexed keywords

ANTINEOPLASTIC AGENT; CD8 ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; THYMOPENTIN; THYMOPENTIN THYMOSIN ALPHA1 FUSION PEPTIDE; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG PROTEIN BINDING; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; TREATMENT DURATION;

IMMUNOREGULATORY ACTIVITY; SURFACE PLASMON RESONANCE; SYNERGISTIC ANTI-TUMOR ACTIVITY; THYMOSIN Α1-THYMOPENTIN; TOLL-LIKE RECEPTOR 2;

ANIMALS; ANTIGENS, CD86; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATROPHY; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; HISTOCOMPATIBILITY ANTIGENS CLASS I; HYDROCORTISONE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEIN BINDING; SKIN NEOPLASMS; SURFACE PLASMON RESONANCE; THYMOCYTES; THYMOPENTIN; THYMOSIN; THYMUS GLAND; TIME FACTORS; TOLL-LIKE RECEPTOR 2; TUMOR BURDEN;

EID: 84880507567     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.006     Document Type: Article

References (40)

1. Lunin S.M., Glushkova O.V., Khrenov M.O., Novoselova T.V., Parfenyuk S.B., Fesenko E.E., Novoselova E.G. Thymic peptides restrain the inflammatory response in mice with experimental autoimmune encephalomyelitis. Immunobiology 2013, 218:402-407.
2. Singh V.K., Biswas S., Mathur K.B., Haq W., Garg S.K., Agarwal S.S. Thymopentin and splenopentin as immunomodulators, current status. Immunol. Res. 1998, 17:345-368.
3. Cascinelli N., Belli F., Mascheroni L., Lenisa L., Clemente C. Evaluation of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients. Melanoma Res. 1998, 8:83-89.
4. Lee H.W., Lee J.I., Um S.H., Ahn S.H., Chang H.Y., Park Y.K., Hong S.P., Moon Y.M., Han K.H. Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: a prospective randomized, comparative pilot study. J. Gastroenterol. Hepatol. 2008, 23:729-735.
5. Piratvisuth T. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. Hepatol. Int. 2008, 2:140-146.
6. Poo J.L., Sánchez Avila F., Kershenobich D., García Samper X., Torress-Ibarra R., Góngora J., Cano C., Parada M., Uribe M. Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders. Ann. Hepatol. 2008, 7:369-375.
7. Zhang Y., Wu X., Han Y., Mo F., Duan Y., Li S. Novel thymopentin release systems prepared from bioresorbable PLA-PEG-PLA hydrogels. Int. J. Pharm. 2010, 386:15-22.
8. Wolf G.T., Hudson J., Peterson K.A., Poore J.A., McClatchey K.D. Interleukin 2 receptor expression in patients with head and neck squamous carcinoma.Effects of thymosin alpha 1 in vitro. Arch. Otolaryngol. Head Neck Surg. 1989, 115:1345-1349.
9. Baumann C.A., Badamchian M., Goldstein A.L. Thymosin a1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro. Int. J. Immunopharmacol. 2000, 22:1057-1066.
10. Chen J.H., Zhang X.G., Jiang Y.T., Yan L.Y., Tang L., Yin Y.W., Cheng D.S., Chen J., Wang M. Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris. Cancer Immunol. Immunother. 2010, 59:1335-1345.
11. Beuth J., Schierholz J.M., Mayer G. Thymosin alpha(1) application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice. Cancer Lett. 2000, 159:9-13.
12. Moody T.W. Thymosin alpha1 as a chemopreventive agent in lung and breast cancer. Ann. NY. Acad. Sci. 2007, 1112:297-304.
13. Mastino A., Favalli C., Grelli S., Rasi G., Pica F., Goldstein A.L., Garaci E. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int. J. Cancer 1992, 50:493-499.
14. Garaci E., Pica F., Sinibaldi-Vallebona P., Pierimarchi P., Mastino A., Matteucci C., Rasi G. Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. Int. Immunopharmacol. 2003, 3:1145-1150.
15. Sungarian A., Cielo D., Sampath P., Bowling N., Moskal P., Wands J.R., de la Monte S.M. Potential role of thymosin-alpha 1 adjuvant therapy for glioblastoma. J. Oncol. 2009, 2009:302084.
16. Liu L., Shan B., Feng Y. Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus. Cell Immunol. 2009, 258:181-187.
17. Ghosh D., Bose A., Haque E., Baral R. Pretreatment with neem (Azadirachta indica) leaf preparation in Swiss mice diminishes leukopenia and enhances the antitumor activity of cyclophosphamide. Phytother. Res. 2006, 20:814-818.
18. Rinaldi Garaci C., Torrisi M.R., Jezzi T., Frati L., Goldstein A.L., Garaci E. Receptors for thymosin alpha 1 on mouse thymocytes. Cell Immunol. 1985, 91:289-293.
19. Romani L., Bistoni F., Gaziano R., Bozza S., Montagnoli C., Perruccio K., Pitzurra L., Bellocchio S., Velardi A., Rasi G., Di Francesco P., Garaci E. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004, 103:4232-4239.
20. Peng X., Zhang P., Wang X., Chan J., Zhu M., Jiang M., Tuthill C., Wan Y., Dragoi A.M., Chu W.M. Signaling pathways leading to the activation of IKK and MAPK by thymosin alpha. Ann. NY Acad. Sci. 2007, 1112:339-350.
21. Gao D., Zhang X., Zhang J., Wang F. Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization. Arch. Pharm. Res. 2008, 31:1471-1476.
22. Li J., Zheng L., Li P., Wang F. Intein-mediated expression, purification, and characterization of thymosin alpha1-thymopentin fusion peptide in Escherichia coli. Protein Expr. Purif. 2012, 84:1-8.
23. Wang W., Wykrzykowska J., Johnson T., Sen R., Sen J. A NF-kappa B/c-myc-dependent survival pathway is targeted by corticosteroids in immature thymocytes. J. Immunol. 1999, 162:314-322.
24. De Kruyff R.H., Fang Y., Umetsu D.T. Corticosteroids enhance the capacity of macrophages to induce Th2 cytokines synthesis in CD41 lymphocytes by inhibiting IL-12 production. J. Immunol. 1998, 160:2231-2237.
25. Arvinte T., Cudd A., Drake A.F. The structure and mechanism of formation of human calcitonin fibrils. J. Biol. Chem. 1993, 268:6415-6422.
26. Sodhi A., Paul S. Involvement of mitogen-activated protein kinases in the signal transduction pathway of bone marrow-derived macrophage activation in response to in vitro treatment with thymosin alpha 1. Int. Immunopharmacol. 2002, 2:47-58.
27. Rodrigues-Mascarenhas S., dos Santos N.F., Rumjanek V.M. Synergistic effect between ouabain and glucocorticoids for the induction of thymic atrophy. Biosci. Rep. 2006, 26:159-169.
28. Blotta M.H., DeKruyff R.H., Umetsu D.T. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J. Immunol. 1997, 158:5589-5595.
29. Girard D., Regan P.A., Milisen W.B., Retsema J.A., Swindell A.C. Influence of immunosuppression on the pharmacokinetics and pharmacodynamics of azithromycin in infected mouse tissues. J. Antimicrob. Chemother. 1996, 37:21-35.
30. Moody T.W., Tuthill C., Badamchian M., Goldstein A.L. Thymosin 1 inhibits mammary carcinogenesis in Fisher rats. Peptides 2002, 23:1011-1014.
31. Rasi G., Silecchia G., Sinibaldi-Vallebona P., Spaziani E., Pierimarchi P., Sivilia M., Tremiterra S., Garaci E. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int. J. Cancer 1994, 57:701-705.
32. Aptsiauri N., Cabrera T., Garcia-Lora A., Lopez-Nevot M.A., Ruiz-Cabello F., Garrido F. MHC class I antigens and immune surveillance in transformed cells. Int. Rev. Cytol. 2007, 256:139-189.
33. Seliger B., Wollscheid U., Momburg F., Blankenstein T., Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 2001, 61:1095-1099.
34. Giuliani C., Napolitano G., Mastino A., Di Vincenzo S., D'Agostini C., Grelli S., Bucci I., Singer D.S., Kohn L.D., Monaco F., Garaci E., Favalli C. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur. J. Immunol. 2000, 30:778-786.
35. Andersen M.H., Schrama D., Thor Straten P., Becker J.C. Cytotoxic T cells. J. Invest. Dermatol. 2006, 126:32-41.
36. Waldner M., Schimanski C.C., Neurath M.F. Colon cancer and the immune system: the role of tumor invading T cells. World J. Gastroenterol. 2006, 12:7233-7238.
37. Komai-Koma M., Jones L., Ogg G.S., Xu D., Liew F.Y. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc. Natl. Acad. Sci. USA 2004, 101:3029-3034.
38. Zhang Y., Luo F., Cai Y., Liu N., Wang L., Xu D., Chu Y. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J. Immunol. 2011, 186:1963-1969.
39. Myszka D.G. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr. Opin. Biotechnol. 1997, 8:50-57.
40. Asong J., Wolfert M.A., Maiti K.K., Miller D., Boons G.J. Binding and cellular activation studies reveal that toll-like receptor 2 can differentially recognize peptidoglycan from gram-positive and gram-negative bacteria. J. Biol. Chem. 2009, 284:8643-8653.